Experienced biotech people found new company and aim for phase I next year
The people behind Action Pharma and Synact have founded another biotech company to develop a new inflammation drug. The team has appointed Symphogen-founder Kirsten Drejer as chairman of the board and plans to initiate clinical trials already next year.
A new actor has entered the Danish biotech industry. Recently founded Resother Pharma has ambitious plans to make it to the very top with an experimental, innovative inflammation drug - and an experienced team is ready for the task.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
